KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $9.4 billion.

  • Amgen's Cash & Equivalents rose 481.63% to $9.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 billion, marking a year-over-year increase of 481.63%. This contributed to the annual value of $12.0 billion for FY2024, which is 940.24% up from last year.
  • Amgen's Cash & Equivalents amounted to $9.4 billion in Q3 2025, which was up 481.63% from $8.0 billion recorded in Q2 2025.
  • Amgen's Cash & Equivalents' 5-year high stood at $34.7 billion during Q3 2023, with a 5-year trough of $5.2 billion in Q2 2022.
  • In the last 5 years, Amgen's Cash & Equivalents had a median value of $9.3 billion in 2024 and averaged $12.6 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 55823.56% in 2023, then tumbled by 7406.23% in 2024.
  • Over the past 5 years, Amgen's Cash & Equivalents (Quarter) stood at $8.0 billion in 2021, then decreased by 4.51% to $7.6 billion in 2022, then soared by 43.45% to $10.9 billion in 2023, then rose by 9.4% to $12.0 billion in 2024, then fell by 21.11% to $9.4 billion in 2025.
  • Its Cash & Equivalents stands at $9.4 billion for Q3 2025, versus $8.0 billion for Q2 2025 and $8.8 billion for Q1 2025.